Syndax Pharmaceuticals (NASDAQ: SNDX) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Syndax Pharmaceuticals to related businesses based on the strength of its risk, valuation, analyst recommendations, earnings, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
70.7% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Syndax Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Syndax Pharmaceuticals||$1.22 million||-$53.19 million||-4.19|
|Syndax Pharmaceuticals Competitors||$579.41 million||$241.76 million||-6.51|
Syndax Pharmaceuticals’ peers have higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Syndax Pharmaceuticals has a beta of 4.69, meaning that its stock price is 369% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals’ peers have a beta of 1.28, meaning that their average stock price is 28% more volatile than the S&P 500.
This is a breakdown of recent ratings for Syndax Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Syndax Pharmaceuticals Competitors||121||759||1625||59||2.63|
Syndax Pharmaceuticals currently has a consensus target price of $24.29, indicating a potential upside of 104.08%. As a group, “Biopharmaceuticals” companies have a potential upside of 7.77%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than its peers.
This table compares Syndax Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Syndax Pharmaceuticals Competitors||-12,909.13%||34.22%||-20.76%|
Syndax Pharmaceuticals beats its peers on 7 of the 12 factors compared.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.